Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANHEPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting blood coagulation.
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
80 units/kg IV bolus followed by 18 units/kg/hour continuous IV infusion; adjust to maintain aPTT 1.5-2.5 times control.
None Documented
None Documented
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Terminal elimination half-life is dose-dependent: at standard IV doses (100 U/kg), mean t½ = 60 min (range 40–90 min); at high doses (400 U/kg), t½ increases to 150 min due to saturable clearance mechanisms. Clinical context: Short t½ necessitates continuous infusion or frequent subcutaneous dosing for sustained anticoagulation.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Primarily renal excretion of metabolites (desulfated heparin) with a minor biliary/fecal component. Unchanged heparin is not excreted renally; clearance occurs via saturable hepatic metabolism and reticuloendothelial system uptake. Renal excretion accounts for approximately 50% of total clearance at therapeutic doses, while biliary/fecal elimination is <10%.
Category A/B
Category C
Anticoagulant
Anticoagulant